Experiences with
Chronic obstructive pulmonary disease (COPD)Related links
Chronic obstructive pulmonary disease (COPD)
HealthUnlocked contains information from NHS Digital, licensed under the current version of the Open Government Licence
48,816 public posts
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
An update of the long-term follow-up results from the original 300-patient FCR (fludarabine, cyclophosphamide, and rituximab) study initiated at MD Anderson in 1999, Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up, reports ~47% of patients with mutated IGHV
Want to take advantage of all our features? Just log in!
or
Just 5% of therapies tested in animals end up as as human drugs, new study shows. CLL research has particular challenges due to the TME
There's a long and challenging journey from microscope observations of cancer cells hopefully dying while exposed to candidate therapies, that is, 'in vitro' testing, to successful in vivo human studies, clinical trials and eventual approval. Not only does the therapy need to kill the cancer cells with
Leukemia-associated macrophages, their role in the CLL Tumor Micro-environment and how they affect progression and therapy response
Understanding how the CLL Tumor Micro-environment (TME) functions is crucial to improving CLL therapy. CLL cells are not as robust as healthy B cells and they rely on their created TME in the nodes and bone marrow for their survival. That's why it's so easy to kill CLL cells with in vitro testing - checking